Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VRC CHKVLP059 00 VP

Drug Profile

VRC CHKVLP059 00 VP

Alternative Names: Alum-adjuvanted chikungunya virus-like particle vaccine; Chikungunya virus virus-like particle vaccine; Chikungunya-virus-vaccine-VRC; CHIKV-VLP; PXVX 0317; VRC-CHKVLP059-00-VP

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases
  • Developer Bavarian Nordic; Emergent BioSolutions; National Institute of Allergy and Infectious Diseases; Walter Reed Army Institute of Research
  • Class Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Chikungunya virus infections

Most Recent Events

  • 23 Feb 2024 Bavarian Nordic announces intention to submit Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Chikungunya virus infections in the first half of 2024
  • 23 Feb 2024 The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) grants accelerated assessment for the upcoming Marketing Authorization Application (MAA) for VRC CHKVLP059 00 VP
  • 30 Aug 2023 Emergent BioSolutions initiates a phase III trial in Chikungunya virus infections (Prevention) in USA (NCT06007183)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top